<SEC-DOCUMENT>0001193125-21-319698.txt : 20211104
<SEC-HEADER>0001193125-21-319698.hdr.sgml : 20211104
<ACCEPTANCE-DATETIME>20211104114902
ACCESSION NUMBER:		0001193125-21-319698
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20211104
FILED AS OF DATE:		20211104
DATE AS OF CHANGE:		20211104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		211378880

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d177836d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of November, 2021. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-40673</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Cybin Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name
of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>100 King
Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9746;</FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule
101(b)(1) only permits the submission in paper of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> if submitted solely to provide an attached annual report to security holders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule
101(b)(7) only permits the submission in paper of a Form <FONT STYLE="white-space:nowrap">6-K</FONT> if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as
the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form <FONT
STYLE="white-space:nowrap">6-K</FONT> submission or other Commission filing on EDGAR. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>CYBIN INC.</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: November&nbsp;4, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:0pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Doug Drysdale</I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Doug Drysdale</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT INDEX </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="d177836dex991.htm">News Release dated November&nbsp;4, 2021 </A></P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d177836dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g177836g1104192835465.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Cybin Granted DEA Schedule I Manufacturing License </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The Company Also Welcomes Leah Gibson as its New Vice </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">President of Investor Relations </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TORONTO,
CANADA </B>&#150; November&nbsp;4, 2021 &#150; <U>Cybin</U><U> Inc.</U> (<U>NEO:CYBN</U>) (<U>NYSE American:CYBN</U>) (&#147;<B>Cybin</B>&#148; or the &#147;<B>Company</B>&#148;), a biopharmaceutical company focused on progressing &#147;Psychedelics
to Therapeutics<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>&#148;, today announced that the Company has been granted a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (&#147;DEA&#148;). The DEA license is a federal
requirement for any investigators who intend to study, produce, analyze or otherwise work with Schedule I controlled substances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DEA license is for
the Company&#146;s research lab in the Boston area. The license will allow the Company to further become a hub for innovation and drug discovery. Previously, the Company conducted much of its research and development (&#147;R&amp;D&#148;) work
through globally licensed research organizations in the U.S., Canada, and the U.K., and through certain <FONT STYLE="white-space:nowrap">in-house</FONT> capabilities. With the DEA license, the Company will be able to vastly expand its internal
R&amp;D capabilities to support innovative drug discovery and delivery involving Schedule I compounds.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased with the progression of our
clinical and regulatory efforts since the Company&#146;s formation. This new license further positions the Company as a truly integrated biopharmaceutical company that can continue to work towards progressing Psychedelics to Therapeutics,&#148; said
Doug Drysdale, Cybin&#146;s Chief Executive Officer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is also pleased to announce the appointment of Leah Gibson to the position of Vice President of
Investor Relations. Leah is a life sciences investor relations leader with more than 18 years of experience in corporate and shareholder communications, and business strategy development. She has spearheaded multiple strategic investor relations
programs including an award-winning and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> program responsible for driving $1.1B in institutional open-market investments over 12 months and increasing
international shareholder presence. Leah has vast experience in working with <FONT STYLE="white-space:nowrap">small-cap</FONT> and <FONT STYLE="white-space:nowrap">large-cap</FONT> publicly traded biotechnology companies, including a $60B <FONT
STYLE="white-space:nowrap">large-cap</FONT> biotechnology company focused on creating transformative medicines for serious diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a transition with
Leah Gibson becoming the new Vice President of Investor Relations, the Company also today announced that John Kanakis will step down from his Chief Business Officer position which was primarily focused on the management of investor and media
relations functions. He will continue with the Company in a role to focus on M&amp;A and business development opportunities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Cybin </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally-recognized scientists, on a mission to
create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the USA, UK and Ireland. The Company is focused on progressing Psychedelics to
Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Notes and Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain
statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin&#146;s future, strategy,
plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words &#147;believe&#148;, &#147;expect&#148;, &#147;aim&#148;, &#147;intend&#148;, &#147;plan&#148;, &#147;continue&#148;, &#147;will&#148;,
&#147;may&#148;, &#147;would&#148;, &#147;anticipate&#148;, &#147;estimate&#148;, &#147;forecast&#148;, &#147;predict&#148;, &#147;project&#148;, &#147;seek&#148;, &#147;should&#148; or similar expressions or the negative thereof, are
forward-looking statements. Forward-looking statements in this news release include statements regarding the Company&#146;s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens
to potentially treat psychiatric disorders. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements are based on reasonable assumptions and estimates of management of the
Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or
achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of
the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company
operates; and the risk factors set out in the Company&#146;s management&#146;s discussion and analysis for the period ended June&nbsp;30, 2021 and the Company&#146;s listing statement dated November&nbsp;9, 2020, which are available under the
Company&#146;s profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or
believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated,
estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions,
projections, or other factors, should they change, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybin makes no medical, treatment or health benefit claims about
Cybin&#146;s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic
compounds or nutraceutical products. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds or
nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality,
consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may
have a material adverse effect on Cybin&#146;s performance and operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have
approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor&nbsp;&amp; Media Contacts:</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Leah Gibson </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cybin Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>leah@cybin.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim Regan/Scott Eckstein </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KCSA Strategic Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>cybin@kcsa.com</U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lisa M. Wilson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">In-Site</FONT>
Communications, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>lwilson@insitecony.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g177836g1104192835465.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g177836g1104192835465.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #2 2,# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYQ@Y)KTBKJTI4Y<LMQ)IJZ"BBBLQA1110 4444 %%%% !1110 4444 %%%%
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M'GUGPK]KMT+7.GMYP ZE,?,/RY_"OGP'H0?<&O=P<U.BEVT.:HK2/L"BN?\
M!>OP>(O#%G=QR*TRH(YUSRK@8.?KU_&N@KQ)1<9.+Z'0G=7"BHKFY@L[=Y[F
M:.&%!EGD8* /J:\D\8_%Y2LECX:Y)^5KYEX'^X#U^IJZ5"=5VBA2DH[G6>-_
MB%8^%(&MH=MSJCK\D /"?[3^@]N]<)\-;GQ#XD\;R:K<W]R]O"I,^7/EG/1
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
